Humanwell Healthcare's (SHA:600079) unit, Yichang Humanwell Pharmaceutical, received registration certificates from China's National Medical Products Administration for carbamazepine extended-release capsules (II), according to a Shanghai bourse filing on Tuesday.
The certificates, which are valid until July 20, 2031, cover the specifications of 100 milligrams, 200 mg and 400 mg.
The drug is used for the treatment of epilepsy and trigeminal neuralgia.